Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study

被引：5

作者：

Soto, Caitlin L. ^{[1
]}

Hsu, Alice J. ^{[1
]}

Lee, Jae Hyoung ^{[2
]}

Dzintars, Kathryn ^{[1
]}

Choudhury, Rebecca ^{[3
]}

Jenkins, Timothy C. ^{[4
]}

Mccreary, Erin K. ^{[5
]}

Quartuccio, Katelyn S. ^{[6
]}

Stohs, Erica J. ^{[7
]}

Zimmerman, Matty ^{[1
]}

Tamma, Pranita D. ^{[2
,8
]}

机构：

[1] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD USA

[2] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21287 USA

[3] Montefiore Med Ctr, Dept Med, Bronx, NY USA

[4] Denver Hlth, Dept Med, Denver, CO USA

[5] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA USA

[6] Univ Rochester, Med Ctr, Dept Pharm, Rochester, NY 14627 USA

[7] Univ Nebraska, Dept Med, Med Ctr, Omaha, NE USA

[8] Johns Hopkins Univ, Dept Pediat, Sch Med, 200 North Wolfe St,Rubinstein Bldg,Rm 3149, Baltimore, MD 21287 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2024年 / 78卷 / 01期

关键词：

carbapenem-resistant Enterobacterales; bacteremia; ceftazidime-avibactam; meropenem-vaborbactam;

D O I：

10.1093/cid/ciad476

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 US hospitals, patients receiving short courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days).

引用

页码：27 / 30

页数：4

共 50 条

[1] Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study
Zhou, Chaoe
Jin, Longyang
Wang, Qi
Wang, Xiaojuan
Chen, Fengning
Gao, Yue
Zhao, Chunjiang
Chen, Hongbin
Cao, Bin
Wang, Hui
INFECTION AND DRUG RESISTANCE, 2021, 14 : 731 - 742
[2] Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections
Park, Se Yoon
Baek, Yae Jee
Kim, Jung Ho
Seong, Hye
Kim, Bongyoung
Kim, Yong Chan
Yoon, Jin Gu
Heo, Namwoo
Moon, Song Mi
Kim, Young Ah
Song, Joon Young
Choi, Jun Yong
Park, Yoon Soo
INFECTION AND CHEMOTHERAPY, 2024, 56 (03): : 308 - 328
[3] Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales
Chen, Liang
Han, Xiudi
Li, YanLi
Li, Minghui
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (09)
[4] Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study
Almangour, Thamer A.
Ghonem, Leen
Aljabri, Ahmad
Alruwaili, Alya
Al Musawa, Mohammed
Damfu, Nader
Almalki, Mesfer S.
Alattas, Majda
Abed, Hossam
Naeem, Doaa
Almalki, Nawaf
Alhifany, Abdullah A.
INFECTION AND DRUG RESISTANCE, 2022, 15 : 211 - 221
[5] Clinical and genomic characterization of carbapenem-resistant Enterobacterales bloodstream infections in patients with hematologic malignancies
Chen, Yi
Huang, Jiangqing
Dong, Luyan
Xu, Binbin
Li, Lei
Zhao, Zhichang
Li, Bin
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
[6] The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China
Zou, Dongna
Yao, Guangyue
Shen, Chengwu
Ji, Jinru
Ying, Chaoqun
Wang, Peipei
Liu, Zhiying
Wang, Jun
Jin, Yan
Xiao, Yonghong
FRONTIERS IN MICROBIOLOGY, 2021, 12
[7] Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study
Russo, Alessandro
Bassetti, Matteo
Ceccarelli, Giancarlo
Carannante, Novella
Losito, Angela Raffaella
Bartoletti, Michele
Corcione, Silvia
Granata, Guido
Santoro, Antonella
Giacobbe, Daniele Roberto
Peghin, Maddalena
Vena, Antonio
Amadori, Francesco
Segala, Francesco Vladimiro
Giannella, Maddalena
Di Caprio, Giovanni
Menichetti, Francesco
Del Bono, Valerio
Mussini, Cristina
Petrosillo, Nicola
De Rosa, Francesco Giuseppe
Viale, Pierluigi
Tumbarello, Mario
Tascini, Carlo
Viscoli, Claudio
Venditti, Mario
JOURNAL OF INFECTION, 2019, 79 (02) : 130 - 138
[8] Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections
Neuner, Elizabeth A.
Yeh, Jun-Yen
Hall, Gerri S.
Sekeres, Jennifer
Endimiani, Andrea
Bonomo, Robert A.
Shrestha, Nabin K.
Fraser, Thomas G.
van Duin, David
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 69 (04) : 357 - 362
[9] Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan
Oka, Keisuke
Matsumoto, Akane
Tetsuka, Nobuyuki
Morioka, Hiroshi
Iguchi, Mitsutaka
Ishiguro, Nobuhisa
Nagamori, Tsunehisa
Takahashi, Satoshi
Saito, Norihiro
Tokuda, Koichi
Igari, Hidetoshi
Fujikura, Yuji
Kato, Hideaki
Kanai, Shinichiro
Kusama, Fumiko
Iwasaki, Hiromichi
Furuhashi, Kazuki
Baba, Hisashi
Nagao, Miki
Nakanishi, Masaki
Kasahara, Kei
Kakeya, Hiroshi
Chikumi, Hiroki
Ohge, Hiroki
Azuma, Momoyo
Tauchi, Hisamichi
Shimono, Nobuyuki
Hamada, Yohei
Takajo, Ichiro
Nakata, Hirotomo
Kawamura, Hideki
Fujita, Jiro
Yagi, Tetsuya
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 29 : 247 - 252
[10] Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study
Bulman, Zackery P.
Cao, Lishan
Curry, Brooke N.
Biagi, Mark
Vivo, Amanda
Suda, Katie J.
Evans, Charlesnika T.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (05)

← 1 2 3 4 5 →